July 26, 2007 - - 8-K: Current report filing | Becton, Dickinson and Company (BDX)

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com


News Release

Contact:
Patricia A. Spinella, Investor Relations 201-847-5453
Colleen T. White, Corporate Communications 201-847-5369

BD ANNOUNCES RESULTS FOR THIRD FISCAL QUARTER

Reports third-quarter earnings per share from continuing operations of 95 cents, an increase of 14% from the prior years quarter
Raises guidance for full fiscal year 2007 earnings per share from continuing operations to $3.81 to $3.83 from $3.76 to $3.80, excluding specified items

Franklin Lakes, NJ (July 26, 2007) BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of $1.631 billion for the third fiscal quarter ended June 30, 2007, representing an increase of 12 percent over the prior year period. This quarters growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for 3 percentage points of the increase in quarterly revenues.

We are pleased with our strong results this quarter, with each of our three segments contributing to our growth, said Edward J. Ludwig, Chairman, President and Chief Executive Officer. The combination of solid revenue growth and continued margin improvement is allowing us to increase our investment in innovation while at the same time driving double-digit increases in earnings. These results, along with our expectations for the remainder of fiscal 2007, have enabled us to once again increase our earnings outlook for the year.

Analysis of Third Quarter and Nine-Month Periods of Fiscal Year 2007 and 2006 Earnings
Reported diluted earnings per share from continuing operations were 95 cents for the third quarter of fiscal 2007. The following analysis (Table 1) of diluted earnings per share from continuing operations for the third quarters of fiscal 2007 and 2006 identifies specified items that affect comparability of results between periods. As illustrated, third quarter fiscal 2007 diluted earnings per share from continuing operations of 98 cents, which exclude a specified item, increased by 18 percent over comparable third quarter fiscal 2006 diluted earnings per share from continuing operations of 83 cents. For the nine-month periods, diluted earnings per share from continuing operations of $2.86 for fiscal 2007, which exclude specified items, increased by 14 percent over comparable fiscal 2006 diluted earnings per share from continuing operations of $2.50, which exclude specified items.

(Table 1)	Three Months Ended June 30,							Nine Months Ended June 30,
	FY2007			FY2006		% Change		FY2007			FY2006				% Change


Diluted EPS from Continuing Operations:	$	0.95		$	0.83	14	%	$	2.38		$	2.33			2	%

Specified Items:
In-Process Research and Development Charge		0.03	(1)		-				0.48	(2)		0.21		(2)
Insurance Settlement		-			-				-			(0.04	)	(3)
		0.03			-				0.48			0.17
Diluted EPS from Continuing Operations
Excluding Specified Items:	$	0.98		$	0.83	18	%	$	2.86		$	2.50			14	%

⁽¹⁾Represents the effect on diluted earnings per share from continuing operations of an in-process research and development (IPR&D) charge recorded in the third quarter of fiscal 2007 related to the acquisition of Plasso Technology, Ltd. on May 4, 2007 for approximately $10 million.

⁽²⁾Represents the effect on diluted earnings per share from continuing operations of the IPR&D charges recorded in the third and first quarters of fiscal 2007 related to the Plasso and TriPath acquisitions, respectively, and in the second quarter of fiscal 2006 related to the GeneOhm acquisition.

⁽³⁾Represents the effect on diluted earnings per share from continuing operations in fiscal 2006 related to proceeds received from insurance settlements associated with the Companys previously owned latex glove business.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $882 million, representing an increase of 10 percent from the prior year period. For the nine-month period ended June 30, 2007, the BD Medical segment reported 10 percent revenue growth. Strong sales in the Pharmaceutical Systems unit continued to significantly contribute to the growth of the segment.

In the BD Diagnostics segment, worldwide revenues for the quarter were $492 million, representing an increase of 15 percent from the prior years quarter. This growth includes $27 million of revenues from TriPath, which was acquired at the end of the first quarter of fiscal 2007. The Preanalytical Systems unit of the segment reported revenue growth of 9 percent. Third quarter revenues in the Diagnostic Systems unit of the segment increased 23 percent, again including revenues from the TriPath acquisition. For the nine-month period ended June 30, 2007, the BD Diagnostics segment reported 9 percent revenue growth.

In the BD Biosciences segment, worldwide revenues for the quarter were $258 million, representing an increase of 13 percent from the prior years quarter. Flow cytometry instrument and reagent sales, as well as sales of advanced bioprocessing products, contributed to growth. For the nine-month period ended June 30, 2007, the BD Biosciences segment reported 12 percent revenue growth, resulting from continued strong sales of those same products.

Geographic Results
Third quarter revenues in the U.S. were $768 million, representing an increase of 10 percent over the prior year period, and include $27 million of revenues from TriPath. Revenues outside the U.S. were $863 million, representing an increase of 13 percent over the prior year period. Approximately 6 percentage points of the increase in international revenues resulted from the favorable impact of foreign currency translation.

For the nine-month period ended June 30, 2007, revenues in the U.S. were $2.243 billion, representing an increase of 10 percent over the prior year period. Revenues outside of the U.S. were $2.466 billion, representing an increase of 10 percent over the prior year period. Approximately 5 percentage points of the increase in international revenues relate to the favorable impact from foreign currency translation.

Fiscal 2007 Outlook for Full Year
The following analysis (Table 2) of estimated diluted earnings per share from continuing operations for the full fiscal year identifies specified items that affect the comparability of results between periods. As illustrated, the Company estimates that diluted earnings per share from continuing operations, excluding specified items, for the full fiscal year 2007 will be in the $3.81 to $3.83 range, representing an increase of approximately 14 to 15 percent over diluted earnings per share from continuing operations, excluding specified items, of $3.34 for the fiscal year 2006.

(Table 2)	Twelve Months Ended
	September 30,
	FY2007	FY2006			% Change
	(Estimated)

Diluted EPS from Continuing Operations:	$3.33-$3.35	$	3.18		5	%

Specified Items:
In-Process Research and Development Charge⁽¹⁾	0.48		0.21
Insurance Settlement⁽²⁾	-		(0.04	)
Rounding	-		(0.01	)
	0.48		0.16
Diluted EPS from Continuing Operations
Excluding Specified Items:	$3.81-$3.83	$	3.34		14%-15	%

⁽¹⁾Represents the effect on diluted earnings per share from continuing operations of the IPR&D charges recorded in the third and first quarters of fiscal 2007 related to the Plasso and TriPath acquisitions, respectively, and in the second quarter of fiscal 2006 related to the GeneOhm acquisition.

⁽²⁾Represents the effect on diluted earnings per share from continuing operations in fiscal 2006 related to proceeds received from insurance settlements associated with the Companys previously owned latex glove business.

Conference Call Information
A conference call regarding BDs third fiscal quarter results and its expectations for the full fiscal year will be broadcast live on BDs website, www.bd.com/investors, at 10:00 a.m. (ET) Thursday, July 26, 2007. The conference call will be available for replay on BDs website, www.bd.com/investors, or at 1-800-475-6701 (domestic) and 1-320-365-3844 (international), using access code 879048, through the close of business on Thursday, August 2, 2007.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving peoples health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Companys capabilities are instrumental in combating many of the worlds most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life

science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

***

This press release, including the section entitled Fiscal 2007 Outlook for Full Year, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BDs performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BDs products; fluctuations in costs and availability of raw materials and in BDs ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BDs filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BDs filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	Three Months Ended June 30,
		2007			2006		% Change

REVENUES	$	1,631,159		$	1,457,347		11.9

Cost of products sold		791,071			719,515		9.9
Selling and administrative		412,164			374,565		10.0
Research and development		92,993			76,699		21.2
Acquired in-process research and development		7,394			-		NM
TOTAL OPERATING COSTS
AND EXPENSES		1,303,622			1,170,779		11.3

OPERATING INCOME		327,537			286,568		14.3

Interest expense		(11,598	)		(15,425	)	(24.8	)
Interest income		11,938			12,146		(1.7	)
Other expense, net		1,774			(2,385	)	NM

INCOME FROM CONTINUING OPERATIONS BEFORE
INCOME TAXES		329,651			280,904		17.4

Income tax provision		89,182			69,834		27.7

INCOME FROM CONTINUING OPERATIONS		240,469			211,070		13.9

INCOME/(LOSS) FROM DISCONTINUED OPERATIONS
NET OF INCOME TAX PROVISION/(BENEFIT) OF
$2,704 AND $(2,865), RESPECTIVELY		4,340			(4,697	)	NM

NET INCOME	$	244,809		$	206,373		18.6

EARNINGS PER SHARE

Basic:
Income from continuing operations	$	0.98		$	0.86		14.0
Income/(loss) from discontinued operations	$	0.02		$	(0.02	)	NM
Net income	$	1.00		$	0.84		19.0

Diluted:
Income from continuing operations	$	0.95		$	0.83		14.5
Income/(loss) from discontinued operations	$	0.02		$	(0.02	)	NM
Net income (1)	$	0.96		$	0.81		18.5


AVERAGE SHARES OUTSTANDING

Basic		244,918			246,633
Diluted		254,128			255,070

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

Page 1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Three Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)

	2007
	As			Plasso		Excluding
	Reported			IPR&D (1)		Item


Operating Income	$	327,537		$	7,394	$	334,931
as a % of revenues		20.1	%				20.5	%

Income from continuing operations		240,469			7,394		247,863
as a % of revenues		14.7	%				15.2	%

Diluted earnings per share
Income from continuing operations	$	0.95		$	0.03	$	0.98

(1) Represents the Acquired in-process research and development charge of $7,394 related to the Plasso acquisition.

Page 2

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	Nine Months Ended June 30,
		2007			2006		% Change

REVENUES	$	4,708,607		$	4,275,401		10.1

Cost of products sold		2,264,544			2,084,227		8.7
Selling and administrative		1,202,879			1,069,914		12.4
Research and development		259,620			219,473		18.3
Acquired in-process research and development		122,133			53,300		NM
TOTAL OPERATING COSTS
AND EXPENSES		3,849,176			3,426,914		12.3

OPERATING INCOME		859,431			848,487		1.3

Interest expense		(36,152	)		(51,990	)	(30.5	)
Interest income		37,138			43,808		(15.2	)
Other expense, net		5,278			(3,999	)	NM

INCOME FROM CONTINUING OPERATIONS BEFORE
INCOME TAXES		865,695			836,306		3.5

Income tax provision		258,636			238,076		8.6

INCOME FROM CONTINUING OPERATIONS		607,059			598,230		1.5

INCOME (LOSS) FROM DISCONTINUED OPERATIONS
NET OF INCOME TAX PROVISION/(BENEFIT) OF
$14,066 AND $(12,127), RESPECTIVELY		23,162			(19,929	)	NM

NET INCOME	$	630,221		$	578,301		9.0

EARNINGS PER SHARE

Basic:
Income from continuing operations	$	2.47		$	2.42		2.1
Income (loss) from discontinued operations	$	0.09		$	(0.08	)	NM
Net income (1)	$	2.57		$	2.34		9.8

Diluted:
Income from continuing operations	$	2.38		$	2.33		2.1
Income (loss) from discontinued operations	$	0.09		$	(0.08	)	NM
Net income	$	2.47		$	2.25		9.8

AVERAGE SHARES OUTSTANDING

Basic		245,296			247,588
Diluted		255,129			256,500

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

Page 3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Nine Months Ended June 30,
(Unaudited; Amounts in thousands, except per-share data)

	2007
		As			TriPath		Plasso		Excluding
		Reported			IPR&D (1)		IPR&D (1)		Items


Operating Income	$	859,431		$	114,739	$	7,394	$	981,564
as a % of revenues		18.3	%						20.8	%

Income from continuing operations		607,059			114,739		7,394		729,192
as a % of revenues		12.9	%						15.5	%

Diluted earnings per share
Income from continuing operations	$	2.38		$	0.45	$	0.03	$	2.86

(1)	Represents the Acquired in-process research and development charges of $114,739 and $7,394 related to the TriPath and Plasso acquisitions, respectively.

	2006
		As			Insurance			GeneOhm		Excluding
		Reported			Settlement (1)			IPR&D (2)		Items


Selling and administrative	$	1,069,914		$	17,000		$	-	$	1,086,914
as a % of revenues		25.0	%							25.4	%

Operating Income		848,487			(17,000	)		53,300		884,787
as a % of revenues		19.8	%							20.7	%

Income taxes		238,076			(6,460	)		-		231,616
effective tax rate		28.5	%							26.5	%

Income from continuing operations		598,230			(10,540	)		53,300		640,990
as a % of revenues		14.0	%							15.0	%

Diluted earnings per share
Income from continuing operations	$	2.33		$	(0.04	)	$	0.21	$	2.50

(1)	Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(2)	Represents the Acquired in-process research and development charge of $53,300 related to the GeneOhm acquisition.

Page 4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	Three Months Ended June 30,
		2007		2006	% Change

BD MEDICAL
United States	$	385,546	$	359,146	7.4
International		496,440		442,972	12.1
TOTAL	$	881,986	$	802,118	10.0

BD DIAGNOSTICS
United States	$	272,946	$	233,428	16.9
International		218,579		193,511	13.0
TOTAL	$	491,525	$	426,939	15.1

BD BIOSCIENCES
United States	$	109,593	$	102,547	6.9
International		148,055		125,743	17.7
TOTAL	$	257,648		228,290	12.9

TOTAL REVENUES
United States	$	768,085	$	695,121	10.5
International		863,074		762,226	13.2
TOTAL	$	1,631,159	$	1,457,347	11.9

Page 5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	Nine Months Ended June 30,
		2007		2006	% Change

BD MEDICAL
United States	$	1,146,143	$	1,056,878	8.4
International		1,406,233		1,265,953	11.1
TOTAL	$	2,552,376	$	2,322,831	9.9

BD DIAGNOSTICS
United States	$	781,644	$	686,728	13.8
International		625,512		599,497	4.3
TOTAL	$	1,407,156	$	1,286,225	9.4

BD BIOSCIENCES
United States	$	314,942	$	291,878	7.9
International		434,133		374,467	15.9
TOTAL	$	749,075	$	666,345	12.4

TOTAL REVENUES
United States	$	2,242,729	$	2,035,484	10.2
International		2,465,878		2,239,917	10.1
TOTAL	$	4,708,607	$	4,275,401	10.1

Page 6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)

	United States
		2007		2006	% Change

BD MEDICAL
Medical Surgical Systems	$	238,360	$	230,123	3.6
Diabetes Care		92,116		88,548	4.0
Pharmaceutical Systems		48,692		34,612	40.7
Ophthalmic Systems		6,378		5,863	8.8
TOTAL	$	385,546	$	359,146	7.4

BD DIAGNOSTICS
Preanalytical Systems	$	139,572	$	131,909	5.8
Diagnostic Systems		133,374		101,519	31.4
TOTAL	$	272,946	$	233,428	16.9

BD BIOSCIENCES
Discovery Labware	$	37,907	$	35,665	6.3
Immunocytometry Systems		51,234		47,027	8.9
Pharmingen		20,452		19,855	3.0
TOTAL	$	109,593	$	102,547	6.9

TOTAL UNITED STATES	$	768,085	$	695,121	10.5

Page 7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	International
					% Change
		2007		2006	Reported	FX Neutral	FX Impact

BD MEDICAL
Medical Surgical Systems	$	233,835	$	217,993	7.3	1.6	5.7
Diabetes Care		82,754		75,193	10.1	4.3	5.8
Pharmaceutical Systems		168,057		139,468	20.5	12.6	7.9
Ophthalmic Systems		11,794		10,318	14.3	7.0	7.3
TOTAL	$	496,440	$	442,972	12.1	5.7	6.4

BD DIAGNOSTICS
Preanalytical Systems	$	121,761	$	107,589	13.2	6.8	6.4
Diagnostic Systems		96,818		85,922	12.7	7.7	5.0
TOTAL	$	218,579	$	193,511	13.0	7.2	5.8

BD BIOSCIENCES
Discovery Labware	$	32,561	$	29,356	10.9	6.1	4.8
Immunocytometry Systems		93,331		76,947	21.3	15.5	5.8
Pharmingen		22,163		19,440	14.0	8.0	6.0
TOTAL	$	148,055	$	125,743	17.7	12.2	5.5

TOTAL INTERNATIONAL	$	863,074	$	762,226	13.2	7.1	6.1

Page 8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	Total
					% Change
		2007		2006	Reported	FX Neutral	FX Impact

BD MEDICAL
Medical Surgical Systems	$	472,195	$	448,116	5.4	2.6	2.8
Diabetes Care		174,870		163,741	6.8	4.2	2.6
Pharmaceutical Systems		216,749		174,080	24.5	18.2	6.3
Ophthalmic Systems		18,172		16,181	12.3	7.6	4.7
TOTAL	$	881,986		802,118	10.0	6.4	3.6

BD DIAGNOSTICS
Preanalytical Systems	$	261,333	$	239,498	9.1	6.2	2.9
Diagnostic Systems		230,192		187,441	22.8	20.5	2.3
TOTAL	$	491,525		426,939	15.1	12.5	2.6

BD BIOSCIENCES
Discovery Labware	$	70,468	$	65,021	8.4	6.2	2.2
Immunocytometry Systems		144,565		123,974	16.6	13.0	3.6
Pharmingen		42,615		39,295	8.4	5.5	2.9
TOTAL	$	257,648		228,290	12.9	9.8	3.1

TOTAL REVENUES	$	1,631,159	$	1,457,347	11.9	8.7	3.2

Page 9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)

	United States
		2007		2006	% Change

BD MEDICAL
Medical Surgical Systems	$	711,545	$	672,438	5.8
Diabetes Care		280,255		272,508	2.8
Pharmaceutical Systems		135,961		95,040	43.1
Ophthalmic Systems		18,382		16,892	8.8
TOTAL	$	1,146,143	$	1,056,878	8.4

BD DIAGNOSTICS
Preanalytical Systems	$	403,211	$	380,110	6.1
Diagnostic Systems		378,433		306,618	23.4
TOTAL	$	781,644	$	686,728	13.8

BD BIOSCIENCES
Discovery Labware	$	109,705	$	100,828	8.8
Immunocytometry Systems		146,684		133,691	9.7
Pharmingen		58,553		57,359	2.1
TOTAL	$	314,942	$	291,878	7.9

TOTAL UNITED STATES	$	2,242,729	$	2,035,484	10.2

Page 10

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	International
					% Change
		2007		2006	Reported		FX Neutral		FX Impact

BD MEDICAL
Medical Surgical Systems	$	675,741	$	628,421	7.5		3.0		4.5
Diabetes Care		234,491		217,899	7.6		2.9		4.7
Pharmaceutical Systems		462,540		389,912	18.6		11.5		7.1
Ophthalmic Systems		33,461		29,721	12.6		6.0		6.6
TOTAL	$	1,406,233	$	1,265,953	11.1		5.7		5.4

BD DIAGNOSTICS
Preanalytical Systems	$	342,941	$	308,413	11.2		5.7		5.5
Diagnostic Systems		282,571		291,084	(2.9	)	(6.4	)	3.5
TOTAL	$	625,512	$	599,497	4.3		(0.2	)	4.5

BD BIOSCIENCES
Discovery Labware	$	94,987	$	87,279	8.8		4.8		4.0
Immunocytometry Systems		272,082		226,709	20.0		14.9		5.1
Pharmingen		67,064		60,479	10.9		6.2		4.7
TOTAL	$	434,133	$	374,467	15.9		11.1		4.8

TOTAL INTERNATIONAL	$	2,465,878	$	2,239,917	10.1		5.0		5.1

Page 11

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	Total
					% Change
		2007		2006	Reported	FX Neutral	FX Impact

BD MEDICAL
Medical Surgical Systems	$	1,387,286	$	1,300,859	6.6	4.5	2.1
Diabetes Care		514,746		490,407	5.0	2.9	2.1
Pharmaceutical Systems		598,501		484,952	23.4	17.7	5.7
Ophthalmic Systems		51,843		46,613	11.2	7.0	4.2
TOTAL	$	2,552,376	$	2,322,831	9.9	6.9	3.0

BD DIAGNOSTICS
Preanalytical Systems	$	746,152	$	688,523	8.4	5.9	2.5
Diagnostic Systems		661,004		597,702	10.6	8.9	1.7
TOTAL	$	1,407,156	$	1,286,225	9.4	7.3	2.1

BD BIOSCIENCES
Discovery Labware	$	204,692	$	188,107	8.8	7.0	1.8
Immunocytometry Systems		418,766		360,400	16.2	13.0	3.2
Pharmingen		125,617		117,838	6.6	4.2	2.4
TOTAL	$	749,075	$	666,345	12.4	9.7	2.7

TOTAL REVENUES	$	4,708,607	$	4,275,401	10.1	7.5	2.6

Page 12

Form: 8-K

Documents